‘A Political Gimmick’: Expert on China’s Row With Pfizer

NTD Newsroom
By NTD Newsroom
January 26, 2023China in Focus
share

A highly anticipated COVID-19 drug from the United States is coming away empty-handed from sales talks with virus-hit China. Chinese officials say the American firm that makes it was charging too much. But is the Chinese regime really unable to afford it? An expert says the deal isn’t so simple.

China in Focus Weekly Newsletter
Find out what's really going on in China
By registering for the newsletter, you agree to the Privacy Policy.